An audit on the management of hypophosphataemia on the wards in a district general hospital in the UK
Department of Diabetes and Endocrinology, Royal Albert Edward Infirmary, Wigan, WN1 2NN, UK.
Research Article
World Journal of Biology Pharmacy and Health Sciences, 2024, 19(02), 055–061
Article DOI: 10.30574/wjbphs.2024.19.2.0486
Publication history:
Received on 23 June 2024; revised on 31 July 2024; accepted on 02 August 2024
Abstract:
Hypophosphataemia or low serum phosphate, if severe can be life-threatening. However, mild hypophosphataemia is quite common and usually asymptomatic. Symptomatic hypophosphataemia (normal: 0.8-1.5 mmol/L) is usually observed when serum phosphate falls below 0.3 mmol/L. Complications may include myopathy, rhabdomyolysis, respiratory failure. cardiac arrhythmias, cardiomyopathy, acute heart failure. delirium, seizures, metabolic encephalopathy and coma. Severe hypophosphataemia can also be related to anaemia, infection, osteomalacia, insulin resistance, ileus and renal tubular failure. Therefore, an audit was carried out for 1 month at the beginning of 2024 to find out whether hypophosphataemia was properly managed on the wards in accordance with the prevailing Guidelines. The findings suggested that although blood tests for Parathyroid hormone (PTH), Cortisol and 24 hours urinary phosphate were done in a small number of patients, in most cases, the management of hypophosphataemia was adequate.
Keywords:
Hypophosphataemia; Hypomagnesaemia; Parathyroid hormone; Fibroblast Growth Factor 23; Calcitriol
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0